You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-cell/histiocyte rich LBCL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Tampa (Comprehensive Ablative Bridging Irradiation (CABI),

Recruiting
  • Large B-cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Comprehensive Ablative Bridging Irradiation (CABI)
  • Chimeric Antigen Receptor T-Cell Therapy
  • Tampa, Florida
    Moffitt Cancer Center
Oct 26, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Large B-cell Lymphoma, Lymphoma Trial in Houston (Loncastuximab Tesirine)

Not yet recruiting
  • Large B-cell Lymphoma
  • Lymphoma
  • Loncastuximab Tesirine
  • Houston, Texas
    MD Anderson Cancer Center
Jul 14, 2022

CAR-T Retreatment Trial in Shanghai (axi-cel)

Recruiting
  • CAR-T Retreatment
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Mar 23, 2023

NHL, DLBCL - Diffuse Large B Cell Lymphoma Trial in Netherlands (ARI-0001, Axi-cel)

Recruiting
  • NHL
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Amsterdam, Netherlands
  • +6 more
Nov 30, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Advanced Solid Tumor Trial in Bethesda, Boston (STAR0602)

Recruiting
  • Advanced Solid Tumor
  • Bethesda, Maryland
  • +1 more
Jan 6, 2023

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Jan 20, 2023

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)

Not yet recruiting
  • Large B-cell Lymphoma
  • B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Biospecimen Collection
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Mar 24, 2023

Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
  • Large B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • Shanghai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255

Recruiting
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • NKTR-255 at 1.5 µg/kg
  • +3 more
  • La Jolla, California
  • +26 more
Jan 10, 2023

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Jan 19, 2023

DLBCL, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type Trial in Chicago (Cyclophosphamide, Doxorubicin

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Chicago, Illinois
    Northwestern University
Apr 30, 2021

Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma Trial in Chicago, Boston, Omaha (Pembrolizumab)

Suspended
  • Lymphoma
  • +3 more
  • Chicago, Illinois
  • +3 more
Jan 30, 2023